These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31085108)

  • 21. Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
    Nagaoka T; Osumi H; Ueno T; Ooki A; Wakatsuki T; Nakayama I; Ogura M; Takahari D; Chin K; Matsueda K; Yamaguchi K; Shinozaki E
    Int J Clin Oncol; 2023 Sep; 28(9):1191-1199. PubMed ID: 37349660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
    Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
    Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spatiotemporal Heterogeneity across Metastases and Organ-Specific Response Informs Drug Efficacy and Patient Survival in Colorectal Cancer.
    Zhou J; Li Q; Cao Y
    Cancer Res; 2021 May; 81(9):2522-2533. PubMed ID: 33589516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.
    Vera R; Gomez Dorronsoro M; Lopez-Ben S; Viudez A; Queralt B; Hernandez I; Ortiz-Duran MR; Zazpe C; Soriano J; Amat I; Herrera Cabezón J; Diaz E; Codina-Barreras A; Hernandez-Yagüe X; Quera A; Figueras J
    Clin Transl Oncol; 2014 Aug; 16(8):739-45. PubMed ID: 24338508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
    Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy.
    Zhu HB; Xu D; Zhang XY; Li XT; Xing BC; Sun YS
    Ann Surg Oncol; 2022 Jun; 29(6):3938-3949. PubMed ID: 35013857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
    García-Alfonso P; Cavanagh Podesta M; Muñoz Martín A; Blanco Codeisido M; Calvo A; Peligros I; Corcuera A; Belén Rúperez Blanco A; Custodio-Cabello S; López Trabada D; Martín M; DE Ramón E
    Anticancer Res; 2018 May; 38(5):3069-3077. PubMed ID: 29715142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiomics diagnosed histopathological growth pattern in prediction of response and 1-year progression free survival for colorectal liver metastases patients treated with bevacizumab containing chemotherapy.
    Wei S; Han Y; Zeng H; Ye S; Cheng J; Chai F; Wei J; Zhang J; Hong N; Bao Y; Zhou J; Ye Y; Meng X; Zhou Y; Deng Y; Qiu M; Tian J; Wang Y
    Eur J Radiol; 2021 Sep; 142():109863. PubMed ID: 34343846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
    Froelich MF; Heinemann V; Sommer WH; Holch JW; Schoeppe F; Hesse N; Baumann AB; Kunz WG; Reiser MF; Ricke J; D'Anastasi M; Stintzing S; Modest DP; Kazmierczak PM; Hofmann FO
    Eur Radiol; 2018 Dec; 28(12):5284-5292. PubMed ID: 29882070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
    Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
    Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
    Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
    Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
    Vigano L; Darwish SS; Rimassa L; Cimino M; Carnaghi C; Donadon M; Procopio F; Personeni N; Del Fabbro D; Santoro A; Torzilli G
    Ann Surg Oncol; 2018 Jun; 25(6):1676-1685. PubMed ID: 29488188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
    Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
    AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.
    Pietrantonio F; Orlandi A; Inno A; Da Prat V; Spada D; Iaculli A; Di Bartolomeo M; Morosi C; de Braud F
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):272-81. PubMed ID: 25958297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.